The most recent filing that the company made with the Securities and Exchange Commission revealed that during the third quarter, the Teacher Retirement System of Texas increased its holdings in Vir Biotechnology, INC (NASDAQ: VIR).
This information was obtained by analyzing the disclosure that the company made earlier.
This phenomenon was said to have increased by 107.7% over the previous year.
The fund had a total holding of 23,886 shares of the company’s stock at the end of the period, having acquired an additional 12,388 shares of the company’s stock throughout the period.
At the end of the most recent fiscal quarter, the Teacher Retirement System of Texas had a holding in Vir Biotechnology that was worth $461,000.
Alterations have been made to the percentage of ownership that several other institutional investors and hedge funds have in the company due to these changes.
The Massachusetts Financial Services Company, MA, increased the percentage of Vir Biotechnology in which it was invested by 0.5% during the second quarter.
After purchasing an additional 537 shares during the most recent quarter, Massachusetts Financial Services Co, MA, now owns 105,665 shares of the company’s stock, which has a value of $2,691,000.
This brings the total number of shares owned by the company to 105,665.
During the second quarter, Nisa Investment Advisors LLC saw a rise of 127.3% in the amount of Vir Biotechnology stock it owned as a percentage of the company.
Because of an acquisition made during the most recent quarter in which 560 additional shares were purchased, Nisa Investment Advisors LLC now directly owns 1,000 shares of the company, each of which has a value of $25,000.
This is because each share was purchased during the most recent quarter. US Bancorp DE invested 175.1 percent more in Vir Biotechnology during the second quarter than it did in the previous quarter.
It has been determined that US Bancorp DE’s holdings in the company’s shares are currently worth $25,000 as of right now.
This represents an increase of 625 shares over the most recent three months.
During the third quarter, the Texas Permanent School Fund increased the total number of shares of Vir Biotechnology Company stock owned by 1.5%.
During the most recent quarter, the Texas Permanent School Fund increased its stake in the company by 795 shares, bringing the total number of shares it owns to 54,375, with a market value of $1,048,000.
And lastly, during the company’s third fiscal quarter, the Oregon Public Employees Retirement Fund increased its holdings in Vir Biotechnology by purchasing an additional 3.5% of its shares.
During the most recent reporting period, the Oregon Public Employees Retirement Fund increased its stake in the company by 852 shares, bringing its total ownership to 25,052 shares, with a market value of $483,000.
To the tune of 74.97% of the company’s stock, institutional investors and hedge funds collectively hold the company’s shares.
Several distinct analysts contributed to the creation of recent reports on the stock that were published.
The Street reevaluated the value of shares of Vir Biotechnology and moved them from a “D” rating to a “C-” rating in a report published on Monday, October 10th.
The report was made public by the company. Needham & Company LLC decreased their target price on Vir Biotechnology shares from $35.00 to $32.00 while maintaining their “buy” rating on the company as a whole in a report published on Friday, November 4th.
Morgan Stanley raised their price objective for Vir Biotechnology by $8.00, bringing it up to $30.00, as a result of a study that was made public on Friday, January 27th.
In addition, Morgan Stanley altered the rating of the company’s shares, moving them from “underweight” to “equal weight” in the overall rating.
